Alnylam Pharmaceuticals SG&A Expense (TTM) Insights

Alnylam Pharmaceuticals Inc (ALNY)

274.91 +0.34 (+0.12%) USD | NASDAQ | Sep 27, 16:00

275.08 +0.17 (+0.06%) After-Hours: 20:00

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2004. Upgrade now.

Date	Value
June 30, 2024	856.49M
March 31, 2024	822.78M
December 31, 2023	795.65M
September 30, 2023	807.87M
June 30, 2023	844.55M
March 31, 2023	799.85M
December 31, 2022	770.66M
September 30, 2022	746.70M
June 30, 2022	652.91M
March 31, 2022	628.25M
December 31, 2021	620.64M
September 30, 2021	600.55M
June 30, 2021	625.94M
March 31, 2021	608.52M
December 31, 2020	588.42M
September 30, 2020	578.41M
June 30, 2020	531.28M
March 31, 2020	516.16M
December 31, 2019	479.00M
September 30, 2019	431.42M
June 30, 2019	427.61M
March 31, 2019	399.52M
December 31, 2018	382.36M
September 30, 2018	341.13M
June 30, 2018	272.22M

Date	Value
March 31, 2018	233.32M
December 31, 2017	199.36M
September 30, 2017	159.79M
June 30, 2017	134.53M
March 31, 2017	106.74M
December 31, 2016	89.35M
September 30, 2016	78.71M
June 30, 2016	72.35M
March 31, 2016	68.99M
December 31, 2015	60.61M
September 30, 2015	57.57M
June 30, 2015	51.43M
March 31, 2015	48.32M
December 31, 2014	44.53M
September 30, 2014	38.67M
June 30, 2014	35.54M
March 31, 2014	29.81M
December 31, 2013	27.15M
September 30, 2013	28.99M
June 30, 2013	35.03M
March 31, 2013	40.48M
December 31, 2012	43.72M
September 30, 2012	44.22M
June 30, 2012	40.37M
March 31, 2012	37.57M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (TTM) Range, Past 5 Years

431.42M

Minimum

Sep 2019

856.49M

Maximum

Jun 2024

665.30M

Average

627.10M

Median

SG&A Expense (TTM) Benchmarks